Title : Genetic Variation And Immune Checkpoint Therapy
link : Genetic Variation And Immune Checkpoint Therapy
Genetic Variation And Immune Checkpoint Therapy
Patient response to immune checkpoint therapy is influenced by patient genotype. It may be necessary to determine individual genetic variation before applying this therapy; alternatively, is it possible to adjust therapy to make it more effective even for patients with less optimal (for therapy) immune genotypes. Abstract:
CD8+ T cell-dependent killing of cancer cells requires efficient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to which patient-specific HLA-I genotype influences response to anti-PD-1 or anti-CTLA-4 is currently unknown. We determined the HLA-I genotype of 1,535 advanced cancer patients treated with immune checkpoint blockade (ICB). Maximal heterozygosity at HLA-I loci (A, B, and C) improved overall survival after ICB compared to patients who were homozygous for at least one HLA locus. In two independent melanoma cohorts, patients with the HLA-B44 supertype had extended survival, whereas the HLA-B62 supertype (including HLA-B*15:01) or somatic loss of heterozygosity at HLA-I, was associated with poor outcome. Molecular dynamics simulations of HLA-B*15:01 revealed unique elements that may impair CD8+ T cell recognition of neoantigens. Our results have important implications for predicting response to ICB and for the design of neoantigen-based therapeutic vaccines.
Thus Article Genetic Variation And Immune Checkpoint Therapy
That's an article Genetic Variation And Immune Checkpoint Therapy This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Genetic Variation And Immune Checkpoint Therapy with the link address https://letslifes.blogspot.com/2018/12/genetic-variation-and-immune-checkpoint.html
0 Response to "Genetic Variation And Immune Checkpoint Therapy"
Post a Comment